Hemab Therapeutics closed a $157 million financing to advance a portfolio focused on rare and underserved coagulation disorders, including lead programs moving toward pivotal testing. The funds will support a pivotal trial for sutacimig in Glanzmann thrombasthenia and continued development of HMB‑002 and other programs that aim to improve clotting in Von Willebrand disease and Factor VII deficiency. The round was led by Sofinnova Partners with participation from strategic crossover investors and signals renewed investor appetite for specialty hematology ventures addressing small patient populations where clinical unmet need and pricing models can justify development costs.